SABCS 2023 | Results from the NATALEE trial: impact on current practice

Gabriel N. Hortobagyi, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights how the final results from the Phase III NATALEE (NCT03701334) study might influence the current treatment paradigm of adjuvant treatment decisions for HR+/HER2− early breast cancer patients at risk of recurrence, particularly those with specific clinical and pathological characteristics. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.